Genmab — April 2019
-
-
Lidt skuffende vi falder på positiv dag
-
Genmab-aktien lever sit eget liv.
-
Salvage Daratumumab Reaches High ORR in Relapsed Myeloma Following Allogeneic SCT https://www.onclive.com/web-exclusives/salvage-daratumumab-reaches-high-orr-in-relapsed-myeloma-following-allogeneic-sct
-
Status quo!
-
CT080/ 4- Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104) https://www.abstractsonline.com/pp8/#!/6812/presentation/9888
-
Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia (CLL) http://clincancerres.aacrjournals.org/content/early/2019/04/02/1078-0432.CCR-18-3412
-
Yes E L. Still a lot of cheap shares left. https://oasm.finanstilsynet.dk/dk/vismeddelelse.aspx?aid=26de526d-86f6-4fca-92c3-759c24e04646&atid=337664
-
New questions about the tradeoffs in ‘accelerated’ cancer drug studies
Cancer clinical trials that use surrogate endpoints end up saving relatively little time, a new study finds.
OHSU News (news.ohsu.edu)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind